Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis. Eur Urol 2005;48:386-99 [1] (multiple letters)

European Urology

Volumn 48, Issue 6, 2005, Pages 1059-1060

  Stephan, Carsten ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Jung, Klaus ^a   Roddam, Andrew W ^b   Allen, Naomi E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; BLOOD LEVEL; CANCER INCIDENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; SYSTEMATIC REVIEW; THEORETICAL STUDY;

EID: 27844603950     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.08.011     Document Type: Letter

References (11)

1. A.W. Roddam M.J. Duffy F.C. Hamdy A.M. Ward J. Patnick C.P. Price Use of prostate-specific Antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2–10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399
2. X. Filella J. Alcover R. Molina J.M. Corral P. Carretero A.M. Ballesta Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia Prostate 42 2000 181 185
3. K. Okihara O. Ukimura T. Nakamura Y. Mizutani A. Kawauchi Y. Naya Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? Eur Urol 46 2004 57 64
4. T.A. Stamey C.E. Yemoto Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume J Urol 163 2000 119 126
5. M. Lein M. Kwiatkowski A. Semjonow H.J. Luboldt P. Hammerer C. Stephan A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations J Urol 170 2003 1175 1179
6. K. Okihara C.D. Cheli A.W. Partin H.A. Fritche D.W. Chan L.J. Sokoll Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer J Urol 167 2002 2017 2023
7. C. Stephan K. Jung M. Lein D. Schnorr S.A. Loening Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer J Urol 164 2000 1671 1672
8. I.M. Thompson D.K. Pauler P.J. Goodman C.M. Tangen M.S. Lucia H.L. Parnes Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre N Engl J Med 350 2004 2239 2246
9. T. Keller H. Butz M. Lein M. Kwiatkowski A. Semjonow H.J. Luboldt Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen Clin Chem 51 2005 532 539
10. J.K. Parsons M.K. Brawer C.D. Cheli A.W. Partin R. Djavan Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6–4.0 ng/mL range of total PSA BJU Int 94 2004 47 50
11. C. Stephan H. Cammann K. Jung Viewpoint: Artificial neural networks: has the time come for their use in prostate cancer patients? Nat Clin Pract Urol 2 2005 262 263